OncoMatch/Clinical Trials/NCT07062055
BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases
Is NCT07062055 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Anti-VEGF and Immunotherapy for hepatocellular carcinoma.
Treatment: Anti-VEGF · Immunotherapy — This multicenter, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining bevacizumab and QL1706 with stereotactic body radiotherapy (SBRT) in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) who present with portal vein tumor thrombus (PVTT) or extrahepatic oligometastatic disease. The study aims to determine whether this combination strategy can prolong progression-free survival (PFS), while also improving overall survival (OS), objective response rate (ORR), disease control rate (DCR), and duration of response (DoR), as well as maintaining quality of life (QoL). In addition, the trial will systematically evaluate the safety profile and treatment-related toxicities associated with this regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Prior chemotherapy or systemic anticancer therapy
Cannot have received: systemic anticancer therapy
Prior chemotherapy or systemic anticancer therapy
Lab requirements
Kidney function
adequate kidney function to tolerate radiotherapy and systemic therapy
Liver function
Child-Pugh class A or B (score ≤7); adequate liver function to tolerate radiotherapy and systemic therapy
Cardiac function
adequate heart function to tolerate radiotherapy and systemic therapy
Liver function classified as Child-Pugh class A or B (score ≤7). Adequate organ function (liver, kidney, lung, and heart) to tolerate both local radiotherapy and systemic therapy. Severe impairment of liver, kidney, lung, or cardiac function that would preclude tolerating radiotherapy or systemic treatment [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify